Morgan Stanley’s Vigil Neuroscience VIGL Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | – | Sell |
-13,091
| Closed | -$104K | – | 8388 |
|
|
2025
Q2 | $104K | Sell |
13,091
-87,074
| -87% | -$390K | ﹤0.01% | 6123 |
|
|
2025
Q1 | $178K | Buy |
100,165
+100,154
| +910,491% | +$225K | ﹤0.01% | 5775 |
|
|
2024
Q4 | $19 | Hold |
11
| – | – | ﹤0.01% | 7877 |
|
|
2024
Q3 | $37 | Sell |
11
-19,830
| -100% | -$73.5K | ﹤0.01% | 7673 |
|
|
2024
Q2 | $79.4K | Sell |
19,841
-3,521
| -15% | -$12.1K | ﹤0.01% | 6044 |
|
|
2024
Q1 | $79.7K | Sell |
23,362
-31,552
| -57% | -$98.5K | ﹤0.01% | 6076 |
|
|
2023
Q4 | $186K | Buy |
54,914
+42,555
| +344% | +$219K | ﹤0.01% | 5731 |
|
|
2023
Q3 | $66.6K | Sell |
12,359
-3,266
| -21% | -$22.6K | ﹤0.01% | 6047 |
|
|
2023
Q2 | $147K | Sell |
15,625
-42,719
| -73% | -$404K | ﹤0.01% | 5777 |
|
|
2023
Q1 | $571K | Buy |
58,344
+49,252
| +542% | +$554K | ﹤0.01% | 5178 |
|
|
2022
Q4 | $114K | Buy |
9,092
+8,962
| +6,894% | +$110K | ﹤0.01% | 5926 |
|
|
2022
Q3 | $1K | Sell |
130
-3,208
| -96% | -$23.5K | ﹤0.01% | 7613 |
|
|
2022
Q2 | $7K | Buy |
3,338
+2,462
| +281% | +$9.72K | ﹤0.01% | 7329 |
|
|
2022
Q1 | $7K | Buy |
+876
| New | +$11.6K | ﹤0.01% | 7513 |
|
Other funds holding VIGL
Morgan Stanley's VIGL Position: Q3 2025 in Review
Morgan Stanley sold out of Vigil Neuroscience (VIGL) in Q3 2025, closing a stake of 13,091 shares — an estimated $104K sold.
Morgan Stanley first reported a position in VIGL in Q1 2022 and held it in 14 quarters. The position peaked at $571K in Q1 2023. 2 funds tracked by Wall St. Rank hold VIGL as of Q3 2025.
- Morgan Stanley reported no remaining Vigil Neuroscience position as of Q3 2025 after selling out during the quarter.
- Morgan Stanley sold 13,091 Vigil Neuroscience shares in Q3 2025, an estimated $104K.
- Morgan Stanley first reported a position in Vigil Neuroscience in Q1 2022 and held it in 14 quarters.
- Morgan Stanley's Vigil Neuroscience position peaked at $571K in Q1 2023.
- 2 funds tracked by Wall St. Rank held Vigil Neuroscience as of Q3 2025.
Based on Morgan Stanley's 13F filing for Q3 2025, filed 14 Nov 2025.